whi p154 has been researched along with Peritonitis in 1 studies
WHI P154: an anti-leukemic agent; structure in first source
Peritonitis: INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malaviya, R | 1 |
| Navara, C | 1 |
| Uckun, FM | 1 |
1 other study available for whi p154 and Peritonitis
| Article | Year |
|---|---|
Augmentation of mast cell bactericidal activity by the anti-leukemic drug, 4-(3'bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline.
Topics: Adjuvants, Immunologic; Animals; Cells, Cultured; Drug Evaluation, Preclinical; Escherichia coli; Es | 2002 |